Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
NCT02098473 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPC4046
Study Locations (20)
Arizona
- Mayo Clinic - Arizona — Scottsdale
- Desert Sun Clinical Research, LLC — Tucson
California
- Alliance Clinical Research — Oceanside
- Precision Research Institute, LLC — San Diego
Florida
- University of Florida — Gainesville
- Borland-Groover Clinic — Jacksonville
Illinois
- Northwestern University-Feinberg School of Medicine — Chicago
- Southwest Gastroenterology — Oak Lawn
Maryland
- Gastroenterology and Hepatology Service Walter Reed National Military Medical Center — Bethesda
- Metropolitan Gastroenterology Group Chevy Chase Clinical Research — Chevy Chase
Colorado
- University of Colorado School of Medicine — Aurora
Connecticut
- Connecticut Clinical Research Foundation — Bristol
Georgia
- Children's Center for Digestive Healthcare — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-08-31 |
| Est. Completion | 2017-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02098473
The ClinicalTrials.gov registry entry for NCT02098473 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 73 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02098473 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Arizona, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02098473 about?
NCT02098473 is a clinical study titled "Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis". The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
What is the current status of trial NCT02098473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-08-31. Estimated completion is 2017-01-30.
What conditions does trial NCT02098473 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02098473?
The interventions under investigation include: Placebo (DRUG), RPC4046 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02098473?
This trial is sponsored by Celgene, which has 73 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02098473 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.